Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Retatrutide

GZBF

Eli Lilly · Phase 2 · Recruiting · Enrollment 300

NCT07467447

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Retatrutide (LY3437943) 1 mg once weekly (no escalation)n/rn/rn/rn/rn/r
Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg.n/rn/rn/rn/rn/r
Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation).n/rn/rn/rn/rn/r
Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mgn/rn/rn/rn/rn/r
Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg.n/rn/rn/rn/rn/r
Placebo once weekly (matched escalation schedule to maintain blinding).n/rn/rn/rn/rn/r
Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg.n/rn/rn/rn/rn/r

A count stays a count. This page does not turn a count into a percent.